Greenlight Biosciences Holdings Pbc Quick Ratio (GRNA) starting from the first quarter 2023 to first quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Greenlight Biosciences Holdings Pbc  (NASDAQ: GRNA)

Greenlight Biosciences Holdings Pbc's Quick Ratio

GRNA's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the first quarter 2023, Quick Ratio deteriorated to 1.04 below Greenlight Biosciences Holdings Pbc's average Quick Ratio.

Within Biotechnology & Pharmaceuticals industry 174 other companies have achieved higher Quick Ratio than Greenlight Biosciences Holdings Pbc in first quarter 2023. While Quick Ratio total ranking in the first quarter 2023 has deteriorated compared to the prior quarter from 1520 to 1641.

Explain Quick Ratio?
How much Cash & cash equivalents GRNA´s has?
What are GRNA´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

GRNA Quick Ratio (Mar 31 2023)
Q1		 (Dec 31 2022)
Q4		 (Sep 30 2022)
Q3		 (Jun 30 2022)
Q2		 (Mar 31 2022)
Q1
Y / Y Current Liabilities Change 5.63 % 335.27 % 791.43 % 5223.39 % 3221.41 %
Y / Y Cash & cash equivalent Change -61.13 % 116.55 % 183 % -15.68 % 16.14 %
Quick Ratio MRQ 1.04 1.91 3.03 0.8 2.82
GRNA's Total Ranking # 1641 # 1520 # 1124 # 2116 # 1228
Seq. Current Liabilities Change -12.3 % 9.7 % -41.29 % 87.02 % 261.39 %
Seq. Cash & cash equivalent Change -52.49 % -30.76 % 122.86 % -46.97 % 164.65 %



Quick Ratio first quarter 2023 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 175
Healthcare Sector # 695
Overall Market # 1641


Quick Ratio Statistics
High Average Low
3.03 1.22 0.01
(Sep 30 2022)   (Dec 31 2021)




Financial Statements
Greenlight Biosciences Holdings Pbc's Current Liabilities $ 31 Millions Visit GRNA's Balance sheet
Greenlight Biosciences Holdings Pbc's Cash & cash equivalent $ 32 Millions Visit GRNA's Balance sheet
Source of GRNA's Sales Visit GRNA's Sales by Geography


Cumulative Greenlight Biosciences Holdings Pbc's Quick Ratio

GRNA's Quick Ratio for the trailling 12 Months

GRNA Quick Ratio

 (Mar 31 2023)
12 Months		 (Dec 31 2022)
12 Months		 (Sep 30 2022)
12 Months		 (Jun 30 2022)
12 Months		 (Mar 31 2022)
12 Months
Y / Y Current Liabilities TTM Growth 264.39 % 1012.11 % 2151.02 % 4899.45 % 4639.6 %
Y / Y Cash & cash equivalent TTM Growth 20.4 % 54.47 % 61.83 % 55.9 % 180.96 %
Quick Ratio TTM 1.57 1.92 2.05 2 4.76
Total Ranking TTM # 4715 # 4404 # 4407 # 1725 # 4406
Seq. Current Liabilities TTM Growth 1.09 % 21.86 % 29.81 % 127.88 % 208.53 %
Seq. Cash & cash equivalent TTM Growth -17.32 % 14.25 % 32.86 % -4.07 % 6.08 %

Quick ratio ranking by company, industry and sector >> Back to GRNA Financial Strength Comparisons >> Go to Compare GRNA Quick Ratio to its Competitors

On the trailing twelve months basis Due to fall in Current Liabilities in the Q1 2023 to $31.19 millions, cumulative Quick Ratio decreased to 1.57 above the GRNA average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 187 other companies have achieved higher Quick Ratio than Greenlight Biosciences Holdings Pbc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2022 from 4404 to 4715.

Explain Quick Ratio?
How much Cash & cash equivalents GRNA´s has?
What are GRNA´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 188
Healthcare Sector # 1187
Within the Market # 4715


trailing twelve months Quick Ratio Statistics
High Average Low
1.92 1.05 0.01
(Dec 31 2022)   (Dec 31 2021)




Companies with similar Quick Ratio in the quarter ending Mar 31 2023, within Biotechnology & Pharmaceuticals Industry Quick RatioMar 31 2023 MRQ Cash & cash equivalentMar 31 2023 MRQ Current Liabilities
Scinai Immunotherapeutics Ltd  2.74 $ 4.870  Millions$ 1.780  Millions
Lineage Cell Therapeutics Inc   2.72 $ 46.814  Millions$ 17.225  Millions
Adaptimmune Therapeutics Plc  2.60 $ 165.554  Millions$ 63.631  Millions
Moderna Inc   2.55 $ 8,923.000  Millions$ 3,499.000  Millions
Neurocrine Biosciences Inc   2.39 $ 894.600  Millions$ 374.100  Millions
Cel sci Corporation  2.33 $ 12.365  Millions$ 5.312  Millions
Tcr2 Therapeutics Inc   2.32 $ 110.310  Millions$ 47.473  Millions
Relay Therapeutics Inc   2.29 $ 161.275  Millions$ 70.467  Millions
Amgen Inc   2.22 $ 31,561.000  Millions$ 14,215.000  Millions
Nanostring Technologies Inc   2.10 $ 122.033  Millions$ 57.991  Millions
Seagen Inc   2.09 $ 1,490.272  Millions$ 713.228  Millions
Genfit S a   2.02 $ 87.124  Millions$ 43.098  Millions
Adma Biologics Inc   1.94 $ 69.204  Millions$ 35.629  Millions
Windtree Therapeutics Inc  1.78 $ 4.235  Millions$ 2.374  Millions
Innate Pharma Sa  1.78 $ 79.078  Millions$ 44.393  Millions
Qiagen N v   1.57 $ 1,057.782  Millions$ 672.125  Millions
Vaxart Inc   1.49 $ 23.377  Millions$ 15.683  Millions
Fennec Pharmaceuticals Inc   1.41 $ 5.686  Millions$ 4.020  Millions
Repligen Corp  1.38 $ 618.018  Millions$ 446.230  Millions
Cidara Therapeutics Inc   1.35 $ 47.976  Millions$ 35.663  Millions
Mink Therapeutics Inc   1.32 $ 14.892  Millions$ 11.250  Millions
C4 Therapeutics Inc   1.26 $ 49.476  Millions$ 39.380  Millions
Axcella Health Inc   1.22 $ 12.540  Millions$ 10.253  Millions
Biocardia Inc   1.21 $ 4.857  Millions$ 4.000  Millions
Taysha Gene Therapies Inc   1.16 $ 63.425  Millions$ 54.455  Millions
Aptose Biosciences Inc   1.16 $ 14.088  Millions$ 12.113  Millions
Bio techne Corp  1.11 $ 157.197  Millions$ 141.163  Millions
Orchard Therapeutics Plc  1.10 $ 61.489  Millions$ 55.888  Millions
Protalix Biotherapeutics inc   1.05 $ 33.036  Millions$ 31.515  Millions
Coherus Oncology inc   1.04 $ 128.089  Millions$ 123.407  Millions

Date modified: 2026-09-18T13:11:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.